Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 0.80 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.80 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16218321 | 1.00 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL17827241 | 0.90 | PDE4D (0.82) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL15071020 | 0.89 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3469495 | 0.87 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL16218320 | 0.87 | PDE4D (0.86) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL15060342 | 0.86 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL17554757 | 0.82 | PDE4D (0.78) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL508401 | 0.81 | PDE4D (0.79) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL16210461 | 0.81 | PDE4D (0.68) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL16210952 | 0.81 | PDE4D (0.68) | PDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794603-B1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-06-15 | — | — | EP | claimed |
| US-8940761-B2 | [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-01-27 | — | — | US | claimed |
| EP-2794603-B1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-06-15 | — | — | EP | disclosed |
| EP-2794603-B1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-06-15 | — | — | EP | disclosed |
| US-9181248-B2 | [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-11-10 | — | — | US | disclosed |
| US-9181248-B2 | [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-11-10 | — | — | US | disclosed |
| US-20150105420-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2015-04-16 | — | — | US | disclosed |
| US-20150105420-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2015-04-16 | — | — | US | disclosed |
| US-8940761-B2 | [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-01-27 | — | — | US | disclosed |
| US-8940761-B2 | [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-01-27 | — | — | US | disclosed |
| US-8940761-B2 | [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-01-27 | — | — | US | disclosed |
| US-20140329853-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2014-11-06 | — | — | US | disclosed |
| US-20140329853-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2014-11-06 | — | — | US | disclosed |
| WO-2013092739-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329853-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3A, PDE2A | PDE4D 7/4885PDE4A 1/4885PDE4B 6/4885 |
| US-20150105420-A1 | [1,2,4]TRIAZOLOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE3A, PDE2A | PDE4D 7/4885PDE4A 1/4885PDE4B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.